These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 16235978

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Eplerenone in chronic heart failure with depressed systolic function.
    Volterrani M, Iellamo F.
    Int J Cardiol; 2015 Dec 01; 200():12-4. PubMed ID: 26044084
    [Abstract] [Full Text] [Related]

  • 43. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
    Young M, Plosker GL.
    Pharmacoeconomics; 2001 Dec 01; 19(12):1227-59. PubMed ID: 11772158
    [Abstract] [Full Text] [Related]

  • 44. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
    Plosker GL, Hurst M.
    Pharmacoeconomics; 2001 Dec 01; 19(11):1111-34. PubMed ID: 11735678
    [Abstract] [Full Text] [Related]

  • 45. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial.
    Adamopoulos C, Ahmed A, Fay R, Angioi M, Filippatos G, Vincent J, Pitt B, Zannad F, EPHESUS Investigators.
    Eur J Heart Fail; 2009 Nov 01; 11(11):1099-105. PubMed ID: 19875410
    [Abstract] [Full Text] [Related]

  • 46. [Cost effectiveness of captopril after myocardial infarct; comment].
    Szucs T, Berger K, Schulte-Hillen J, Kleber FX.
    Med Klin (Munich); 1996 Feb 15; 91(2):112-8. PubMed ID: 8850108
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LT, Postma MJ, PREVEND IT Study Group.
    Clin Ther; 2006 Mar 15; 28(3):432-44. PubMed ID: 16750458
    [Abstract] [Full Text] [Related]

  • 49. Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?
    Weir RA, Mark PB, Petrie CJ, Clements S, Steedman T, Ford I, Ng LL, Squire IB, Wagner GS, McMurray JJ, Dargie HJ.
    Am Heart J; 2009 Jun 15; 157(6):1088-96. PubMed ID: 19464421
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Cost-effectiveness of implantable cardioverter-defibrillators.
    Sanders GD, Hlatky MA, Owens DK.
    N Engl J Med; 2005 Oct 06; 353(14):1471-80. PubMed ID: 16207849
    [Abstract] [Full Text] [Related]

  • 53. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.
    Lyseng-Williamson KA, Foster RH.
    Pharmacoeconomics; 2004 Oct 06; 22(2):107-32. PubMed ID: 14731052
    [Abstract] [Full Text] [Related]

  • 54. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A, Scavone C, Vitale C, Sportiello L, Rossi F, Rosano GM, Coats AJ.
    Int J Cardiol; 2015 Dec 01; 200():15-9. PubMed ID: 26404747
    [Abstract] [Full Text] [Related]

  • 55. Eplerenone in patients with systolic heart failure and mild symptoms.
    Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group.
    N Engl J Med; 2011 Jan 06; 364(1):11-21. PubMed ID: 21073363
    [Abstract] [Full Text] [Related]

  • 56. [Economic impact of cardiac resynchronization therapy in patients with heart failure. Available evidence and evaluation of the CRT-Eucomed model for analysis of cost-effectiveness].
    Fattore G, Landolina M, Bontempi L, Cacciatore G, Curnis A, Gulizia M, Padeletti L, Mazzei L, Tavazzi L, Gruppo di Studio congiunto Federazione Italiana di Cardiologia-Assobiomedica di Cardiologia-Assobiomedica "Valutazione del Medello CRT-Eucomed".
    Ital Heart J Suppl; 2005 Dec 06; 6(12):796-803. PubMed ID: 16444923
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL, Willis WD, Foos V.
    Curr Med Res Opin; 2010 Jan 06; 26(1):163-75. PubMed ID: 19919377
    [Abstract] [Full Text] [Related]

  • 59. Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial.
    Iqbal J, Fay R, Adlam D, Squire I, Parviz Y, Gunn J, Pitt B, Zannad F.
    Eur J Heart Fail; 2014 Jun 06; 16(6):685-91. PubMed ID: 24706498
    [Abstract] [Full Text] [Related]

  • 60. Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER).
    Asakura M, Yamamoto H, Asai K, Hanatani A, Hirata K, Hirayakma A, Kimura K, Kobayashi Y, Momomura S, Nakagawa Y, Nishi Y, Saito Y, Satoh Y, Yamada T, Yamashina A, Yasuda S, Yoshikawa T, Kada A, Uesaka H, Kitakaze M, EARLIER investigators and study coordinators.
    Cardiovasc Drugs Ther; 2015 Apr 06; 29(2):179-85. PubMed ID: 25566817
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.